Juhasz Margit, Fackler Nathan, Pham Christine, Mesinkovska Natasha Atanaskova
Drs. Juhasz and Mesinkovska are with the Department of Dermatology at the University of California-Irvine in Irvine, California.
Mr. Fackler is also with Georgetown University's School of Medicine in Washington, D.C.
J Clin Aesthet Dermatol. 2020 Dec;13(12):27-28. Epub 2020 Dec 1.
Dysregulated scar formation can cause hypertrophic scarring, a difficult entity to treat. Although fractionated lasers are a popular therapy for hypertrophic scars, laser-induced epidermal damage might cause pigmentary changes in individuals with darker skin tones. Radiofrequency microneedling delivers ablative energy directly to the dermis and is safe for use in such patients. We present a case of hypertrophic scarring in a patient with Fitzpatrick Skin Type IV treated with a combination of radiofrequency microneedling, topical and intralesional corticosteroids, and intralesional onabotulinumtoxinA. Three weeks posttreatment, scars were significantly improved in both color and texture. The patient did not report any side effects. Based on these results, this novel combination therapy appears to be a promising treatment modality for hypertrophic scars in patients with Fitzpatrick Skin Types IV to VI. However, further large-scale studies will need to be completed to determine long-term efficacy and possible adverse events.
瘢痕形成失调可导致增生性瘢痕,这是一种难以治疗的病症。尽管分次激光是治疗增生性瘢痕的常用方法,但激光引起的表皮损伤可能会导致肤色较深的个体出现色素沉着变化。射频微针直接将消融能量传递至真皮,对这类患者使用安全。我们报告一例 Fitzpatrick 皮肤分型为IV型的患者,采用射频微针、外用和皮损内注射皮质类固醇以及皮损内注射A型肉毒毒素联合治疗增生性瘢痕。治疗后三周,瘢痕的颜色和质地均有显著改善。患者未报告任何副作用。基于这些结果,这种新型联合疗法似乎是治疗 Fitzpatrick 皮肤分型为IV至VI型患者增生性瘢痕的一种有前景的治疗方式。然而,需要完成进一步的大规模研究以确定其长期疗效和可能的不良事件。